Cancer treatments

PureTech Announces Clinical Trial and Supply Agreement with BeiGene to Evaluate LYT-200 and Tislelizumab in Patients with Difficult-to-Treat Solid Tumors

Retrieved on:

Wednesday, July 7, 2021

Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Clinical medicine, Medicine, Cancer treatments, Virotherapy, Cancer immunotherapy, Antineoplastic drugs, Immunotherapy, Chemotherapy, Cancer, Treatment of cancer

In addition, PureTech plans to investigate LYT-200 as a single agent and in combination with other anti-cancer treatments, including chemotherapy and other immunotherapies.

Key Points:

In addition, PureTech plans to investigate LYT-200 as a single agent and in combination with other anti-cancer treatments, including chemotherapy and other immunotherapies.
Tislelizumab has been approved in China for four solid tumor indications and regulatory decisions are pending for two additional indications.
We look forward to evaluating whether LYT-200 in combination with BeiGenes tislelizumab can improve outcomes for patients with metastatic solid tumors.
Under the terms of the agreement, PureTech will maintain control of the LYT-200 program, including global R&D and commercial rights.

Luvme Hair Supporting E-Beauty's Wig Donation Program to Empower Women Undergoing Chemotherapy

Retrieved on:

Wednesday, July 7, 2021

Organ systems, Clinical medicine, Medicine, Cancer treatments, Human hair, Hairdressing, Hair loss, Chemotherapy, Wig, Hair

NEW YORK, July 6, 2021 /PRNewswire/ -- Luvme Hair, a luxury human hair wig brand, has focused on women's health issues for many years.

Key Points:

NEW YORK, July 6, 2021 /PRNewswire/ -- Luvme Hair, a luxury human hair wig brand, has focused on women's health issues for many years.
They kicked off their wig donation drive to benefit the women undergoing chemotherapy treatments.
According to pharmacy times, approximately 65% of individuals undergoing chemotherapy will experience chemotherapy-induced hair loss.
Forty-seven percent of female cancer patients consider hair loss to be the most traumatic aspect of chemotherapy, with 8% of them stating they would decline treatment for fear of hair loss.To support and empower our global community, Luvme Hair plans to help these women in need overcome their hair loss due to chemotherapy through their wig donations program.

OncoSec Enters into a Collaboration Agreement with Merck for a Pivotal Global Phase 3 Study, KEYNOTE-C87, of TAVO™ Combined with KEYTRUDA® for Late-Stage Metastatic Melanoma

Retrieved on:

Tuesday, July 6, 2021

Cancer treatments, Clinical medicine, Drugs, Antineoplastic drugs, Breakthrough therapy, Orphan drugs, Cancer immunotherapy, Pembrolizumab, Melanoma, Nivolumab, Merck & Co.

Under the terms of the Agreement, Merck will provide KEYTRUDA , while OncoSec will provide the investigational drug, TAVO.

Key Points:

Under the terms of the Agreement, Merck will provide KEYTRUDA , while OncoSec will provide the investigational drug, TAVO.
Eligible patients must have Stage III or IV unresectable, metastatic melanoma, and must be refractory to prior checkpoint therapy.
"This Phase 3 collaboration represents a crucial milestone for OncoSec as we advance TAVO through the clinic and toward potential approval globally, and expands upon our initial 2017 clinical collaboration and supply agreement with Merck.
TAVO has received both Orphan Drug and Fast-Track Designation by the U.S. Food & Drug Administration for the treatment of metastatic melanoma.

Knight Therapeutics Announces Health Canada Approval for NERLYNX® (Neratinib) to Treat HER2-Positive Metastatic Breast Cancer

Retrieved on:

Tuesday, July 6, 2021

Clinical medicine, Cancer, Medicine, Cancer treatments, HER2/neu, Breast cancer, Trastuzumab, NeuVax

According to Canadian Cancer Statistics, breast cancer accounts for one-quarter (25%) of all new cancer cases in women2.

Key Points:

According to Canadian Cancer Statistics, breast cancer accounts for one-quarter (25%) of all new cancer cases in women2.
Approximately 27,700 women were diagnosed with breast cancer in 2020, and 5,100 died of the disease in the same year2.
Studies show that up to 20% of breast cancer tumors have an over-expression of the HER2 protein.
Women with breast cancer that over-expresses HER2, referred to as HER2-positive breast cancer, are at greater risk for disease progression and death than women whose tumors do not over-express HER2.

Athenex Provides Update from FDA Type A Meeting Regarding Oral Paclitaxel Plus Encequidar for the Treatment of Metastatic Breast Cancer

Retrieved on:

Tuesday, July 6, 2021

Carbonyl compounds, Drugs, Cancer treatments, Taxanes, Orphan drugs, Bristol-Myers Squibb, Paclitaxel, Protein-bound paclitaxel, Paclitaxel trevatide

The FDA was supportive and encouraged the Company to continue development of oral paclitaxel and encequidar for the treatment of metastatic breast cancer.

Key Points:

The FDA was supportive and encouraged the Company to continue development of oral paclitaxel and encequidar for the treatment of metastatic breast cancer.
We continue to believe that, if approved, oral paclitaxel and encequidar has the potential to address a major unmet need in metastatic breast cancer.
Athenex is also developing oral paclitaxel and encequidar for the treatment of cutaneous angiosarcoma, for which it has received Orphan Drug Designation from the FDA.
Athenex also received Orphan Designations from the European Commission for oral paclitaxel and encequidar for the treatment of soft tissue sarcoma.

FDA Approves Dose Escalation Label Update for Puma Biotechnology’s NERLYNX® (neratinib) in HER2-Positive Early Stage and Metastatic Breast Cancer

Retrieved on:

Thursday, July 1, 2021

HER2-positive breast cancer is often more aggressive than other types of breast cancer, increasing the risk of disease progression and death.

Key Points:

HER2-positive breast cancer is often more aggressive than other types of breast cancer, increasing the risk of disease progression and death.
Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care.
INDICATIONS AND USAGE: NERLYNX is a kinase inhibitor indicated:
As a single agent, for the extended adjuvant treatment of adult patients with early stage HER2-positive breast cancer, to follow adjuvant trastuzumab-based therapy.
Withhold NERLYNX in patients experiencing Grade 3 liver abnormalities and permanently discontinue NERLYNX in patients experiencing Grade 4 liver abnormalities.

Aileron Therapeutics Announces Initiation of Randomized, Double-Blind, Placebo-Controlled Trial of ALRN-6924 in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)

Retrieved on:

Thursday, July 1, 2021

Clinical medicine, Cancer, Medicine, Antineoplastic drugs, Cancer treatments, Lung cancer, Oncology, Antifolates, Pemetrexed, Targeted therapy, Chemotherapy, Treatment of lung cancer

Aileron plans to enroll 60 patients with advanced p53-mutated NSCLC undergoing treatment with first-line carboplatin plus pemetrexed with or without immune checkpoint inhibitors in this Phase 1b trial.

Key Points:

Aileron plans to enroll 60 patients with advanced p53-mutated NSCLC undergoing treatment with first-line carboplatin plus pemetrexed with or without immune checkpoint inhibitors in this Phase 1b trial.
When devising treatment strategies for todays cancer patients, the use of targeted therapies is certainly preferred when possible.
In cancer cells, the cell cycle is unchecked, which leads to uncontrolled cell proliferation, a hallmark of cancer.
Aileron is a clinical stage chemoprotection oncology company focused on fundamentally transforming the experience of chemotherapy for cancer patients.

Achilles Therapeutics Enrolls First US Patient in Ongoing Phase I/IIa Study in Advanced Non-small Cell Lung Cancer

Retrieved on:

Thursday, July 1, 2021

Cancer treatments, Clinical medicine, Drugs, Lung cancer, Breakthrough therapy, Orphan drugs, Antineoplastic drugs, Non-small-cell lung carcinoma, Melanoma, Treatment of lung cancer, Ipilimumab

CHIRON is an open-label, multi-center Phase I/IIa trial evaluating the safety, tolerability, and activity of clonal neoantigen T cell (cNeT) therapy as a single dose in adult patients with advanced metastatic non-small cell lung cancer (NSCLC).

Key Points:

CHIRON is an open-label, multi-center Phase I/IIa trial evaluating the safety, tolerability, and activity of clonal neoantigen T cell (cNeT) therapy as a single dose in adult patients with advanced metastatic non-small cell lung cancer (NSCLC).
This first US patient was enrolled at the Moffitt Cancer Center in Tampa, FL where Dr. Benjamin Creelan is the Principal Investigator.
Achilles is a clinical-stage biopharmaceutical company developing precision T cell therapies targeting clonal neoantigens: protein markers unique to the individual that are expressed on the surface of every cancer cell.
The Company has two ongoing Phase I/IIa trials, the CHIRON trial in patients with advanced non-small cell lung cancer (NSCLC) and the THETIS trial in patients with recurrent or metastatic melanoma.

FDA Approves Component of Treatment Regimen for Most Common Childhood Cancer

Retrieved on:

Wednesday, June 30, 2021

Clinical medicine, Medicine, Antineoplastic drugs, Cancer, Cancer treatments, Asparaginase, Chemotherapy, Leukemia, 7+3

"Today's approval may provide a consistently sourced alternative to a pivotal component of potentially curative therapy for children and adults with this type of leukemia."

Key Points:

"Today's approval may provide a consistently sourced alternative to a pivotal component of potentially curative therapy for children and adults with this type of leukemia."
It is the most common type of childhood cancer.
One component of the chemotherapy regimen is an enzyme called asparaginase that kills cancer cells by depriving them of substances needed to survive.
The most common side effects of Rylaze include hypersensitivity reactions, pancreatic toxicity, blood clots, hemorrhage and liver toxicity.

NANOBIOTIX Announces Initiation of New Clinical Study Evaluating NBTXR3 in Lung Cancer

Retrieved on:

Wednesday, June 30, 2021

In addition to the lung cancer study described above, two phase II studies, each evaluating NBTXR3 in combination with anti-PD-1 for patients with head and neck cancer (inoperable locoregional recurrent amenable to reirradiation and recurrent metastatic with limited PD-L1 expression or refractory); one phase I study evaluating NBTXR3 in combination with chemotherapy for patients with esophageal cancer; and one phase I study evaluating NBTXR3 as a single-agent activated by RT for patients with pancreatic cancer are active and enrolling.

Key Points:

In addition to the lung cancer study described above, two phase II studies, each evaluating NBTXR3 in combination with anti-PD-1 for patients with head and neck cancer (inoperable locoregional recurrent amenable to reirradiation and recurrent metastatic with limited PD-L1 expression or refractory); one phase I study evaluating NBTXR3 in combination with chemotherapy for patients with esophageal cancer; and one phase I study evaluating NBTXR3 as a single-agent activated by RT for patients with pancreatic cancer are active and enrolling.
As previously announced, the first patient has been injected with NBTXR3 in each of the esophageal cancer and pancreatic cancer studies.
The first NBTXR3 injections in the phase II head and neck cancer studies are expected in the second half of 2021.
The clinical collaboration between Nanobiotix and MD Anderson is a collaborator-led expansion of the NBTXR3 development pipeline across indications and therapeutic combinations.